🎯 Background & Rationale
In contemporary pulmonary practice—especially with the expansion of lung cancer screening—multiple pulmonary nodules (MPNs) are frequently encountered. Traditionally, clinicians have relied on the "oversimplification bias," sampling only the radiographically "dominant" lesion and assuming that concurrent nodules share the same pathology. Obtaining tissue from multiple lesions historically carried high procedural risks and technical hurdles. However, with the advent of advanced robotic-assisted bronchoscopy (RAB) combined with cone-beam CT (CBCT) and endobronchial ultrasound (EBUS), simultaneous sampling of MPNs in a single anesthetic session has become feasible, challenging the paradigm that one nodule represents them all.
👥 Study Design & Population
Study Type: Multicenter Observational Study / Registry Analysis (Editorial/Review of Kapp et al., Ann Am Thorac Soc, 2026).
- Population: 191 patients with multiple pulmonary nodules (MPNs) undergoing simultaneous RAB and tissue sampling across 6 centers over a 6-year period (with 167 of these patients also undergoing linear EBUS lymph node staging).
- Intervention: Single-session, multi-target robotic-assisted bronchoscopy and biopsy of MPNs, alongside EBUS staging.
- Comparison: Evaluation of diagnostic performance and histopathologic concordance across sequential targets (first, second, and third sampled nodules).
- Outcomes: Diagnostic yield (DY) using strict consensus criteria, sample adequacy for next-generation sequencing (NGS), lymph node metastasis prevalence via EBUS, and procedure safety.
📈 Methodology & Rigor
The authors of the underlying study utilized a longitudinal, multicenter registry design incorporating 6 centers over 6 years. Rigor is demonstrated by the application of strict, standardized definitions for diagnostic yield according to recent consensus statements. The study systematically evaluated procedural variables, tracking whether sequential sampling (first vs. subsequent nodules) impacted yield, and assessed tissue quality specifically for molecular profiling (NGS). However, limitations inherent to registry designs include potential variations in operator experience, institutional protocols, and uncaptured metrics such as total procedure duration, radiation exposure parameters, and precise ventilation strategies.
🔬 Key Findings [or Planned Endpoints]
- Diagnostic Stability: RAB diagnostic yield remained remarkably consistent regardless of sampling sequence (exceeding 70% whether a lesion was sampled first, second, or third), showing no drop-off due to procedural complexity or atelectasis.
- Histopathologic Discordance: Nearly 1 in 5 patients (approx. 20%) with two malignant nodules demonstrated discordant histopathology, proving that radiographic similarity does not guarantee biological identity.
- Nodal Staging & PET Limitations: Over 10% of patients undergoing concomitant EBUS staging had lymph node metastases; notably, roughly 1/3 of these node-positive patients were PET-negative, and 22% had contralateral parenchymal nodules.
- Tissue Adequacy for NGS: RAB biopsy samples yielded adequate cellularity for next-generation sequencing in 82.6% of non-small cell lung cancer nodules.
- Safety Profile: The overall pneumothorax rate was 7.3%, with only 2.1% requiring a chest tube. No bilateral pneumothoraces were reported despite bilateral sampling.
⚖️ Critical Appraisal
While the multicenter registry provides robust "real-world" data supporting the feasibility and safety of multi-target RAB, inherent limitations remain. The study lacks randomized comparisons against alternative modalities (such as repeat CT-guided biopsies or staged approaches) and does not formally capture radiation exposure metrics (which are known to be significant with CBCT and advanced fluoroscopy) or exact procedure times. Furthermore, rare but catastrophic complications like air embolism were not systematically quantified. Generalizability may also be skewed toward high-volume, experienced academic centers proficient in advanced bronchoscopic navigation.
💡 The Clinical Bottom Line
Assuming the radiographically "dominant" nodule represents the pathology of all concurrent lung lesions is an oversimplification that risks misstaging and mistreating patients. Interventional pulmonologists should abandon the binary bias of single-nodule sampling when confronting MPNs; single-session, multi-target RAB with EBUS staging is safe, maintains high diagnostic yield across sequential targets, yields tissue sufficient for advanced molecular profiling, and fundamentally alters clinical management in a significant proportion of patients.